USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Preventing Biofilms on Indwelling Medical Devices with Novel…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
1046012
Solicitation Year:
2010
Solicitation Topic Code:
BC
Solicitation Number:
Small Business Information
AGILE SCIENCES, INC.
1791 Varsity Dr. RALEIGH, NC -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: SBIR Phase I: Preventing Biofilms on Indwelling Medical Devices with Novel Anti-Biofilm Small Molecules
Agency: NSF
Contract: 1046012
Award Amount: $150,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project describes a new approach for reducing infections associated with indwelling medical devices. Bacteria on medical devices are particularly challenging to treat because they form a protective matrix called a biofilm on the surface of the device. It is very difficult to access bacteria in the biofilm state, and systemic use of antibiotics is generally ineffective against bacteria in biofilms. We have discovered a class of novel small molecules that inhibits bacteria's ability to form biofilms as well as disperses pre-formed bacterial biofilms. This is the only class of small molecules reported that is able to disperse pre-formed biofilms from both gram-positive and gram-negative bacteria. Both gram-positive and gram-negative bacterial biofilms have been identified on medical devices. For this Phase I SBIR, we propose to test the feasibility of incorporating our anti-biofilm compound into medical devices through a covalent bonding technique. The broader impact/commercial potential of this project addresses both health and economic burdens associated with infections of medical devices. Indwelling medical devices are associated with approximately 1 million infections and 50,000 deaths in the US each year, and hundreds of millions of dollars are spent annually treating these infections. Furthermore, infections associated with indwelling medical devices currently account for approximately one half of all hospital-acquired infections. It is estimated that the direct cost of eliminating infections known to be related to device biofilms is approximately $650 million each year.

Principal Investigator:

Stephen R. Brand
9194573308
sbrand@agilesci.com

Business Contact:

Stephen R. Brand
DPhil
9194573308
sbrand@agilesci.com
Small Business Information at Submission:

Agile Sciences Inc.
3309 Milton Rd Raleigh, NC -

EIN/Tax ID: 208755458
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No